



Insulet Corporation to Announce Fourth Quarter and Full Year 2017 Financial Results on February 21, 2018

January 29, 2018

BILLERICA, Mass.--(BUSINESS WIRE)--Jan. 29, 2018-- Insulet Corporation (NASDAQ: PODO) (Insulet or the Company), the leader in [tubeless insulin pump](#) technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the fourth quarter and full year of 2017 on February 21, 2018 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

This press release features multimedia. View the full release here: <http://www.businesswire.com/news/home/20180129005606/en/>

The link to the live call will be available on the Investor Relations section of the Company's website at <http://investors.insulet.com>, "Events and Presentations", and will be archived for future replay. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 3671056.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODO), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet's Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and www.omnipodeurope.com.*

*Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it already does in the United States and Canada.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180129005606/en/>

Source: Insulet Corporation

Investor Relations and Media Contact:

Insulet Corporation
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications
dgordon@insulet.com